Concur on all fronts. Good contributions from the few and Galaxy is a certified bell-end.
All stacking up beautifully, even if their communication is like pulling teeth. Let's not forget this 510k is much more than we expected. Not only are the results a home run along with news on a potential MacDaddy approval pathway, the FDA comparator they have used is the same comparator used in the human trials announcing this quarter. This is not an accident. WHEN these further results come back positive (I can't see anything other than that) Orthocell will see a notable shift in sentiment and a step-change in market action.
Ann: CelGro Study Results Open Up New US Market Access Strategy, page-48
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
66.5¢ |
Change
-0.020(2.92%) |
Mkt cap ! $159.0M | |||
| Open | High | Low | Value | Volume |
| 67.0¢ | 67.0¢ | 65.0¢ | $245.7K | 371.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15000 | 65.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.5¢ | 12621 | 2 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| OCC (ASX) Chart |